BioSpace News Archive

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pralsetinib for the treatment of patients with advanced or metast

Tektronix has shifted its work from supporting vehicle manufacturing to assisting with ventilator production

- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel - - Advancing EVO100 for the Prevention of Urogenital Chlamydia and Gonorrhea - - ~ $136 Million Gross Proceeds Raised; Funding Expected to Carry the Company into Q2 2021 -

PainTEQ, a leading medical device innovator, announced the appointment of Michael Enxing, Chief Commercial Officer of Boston Scientific Corporation, Neuromodulation Division.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the first patient with triple negative breas

AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, announced the appointment of Rita Jain, M.D., to the Company’s Supervisory Board.

International medical imaging IT and cybersecurity company Sectra publishes its Annual Report and Sustainability Report for the 2019/2020 financial year as well as the Board of Directors’ Corporate Governance Report for the corresponding period.

BiondVax Pharmaceuticals Ltd. announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial of BiondVax’s M–001 universal influenza vaccine candidate have now completed their site visits.

July 1, 2020 10:00 UTC IRVING, Texas--( BUSINESS WIRE )-- A study facilitated by Vizient, Inc. and recently published in the Journal of American Medical Association Internal Medicine yielded new insights about patients with presumed penicillin allergies. The study, led by researchers at Massachusetts General Hospital, found that physicians unnecessarily prescribe inferior antibiotic alternatives to patients with documented penicillin allergies. Because 90% of documented penicill

Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir